Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421.

BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the potential to repair damage caused to the cornea as well as treat disease symptoms.

The Phase II/III trial was conducted in the U. in 2020, with over 200 patients. Data support an excellent safety profile, with no serious adverse events (SAEs) and successful completion by 100% of patients taking part in the trial. Importantly, results demonstrate significant improvements (p<0.05) in secondary outcome measures on Day 8: visual analogue scale (VAS) dryness, VAS burning/stinging and VAS photophobia, and most notably a strong trend of improvement in primary outcome corneal repair (p=0.1) at Day 15. The overall results show that BRM421 is safe and well-tolerated with a unique early onset of curative effect.

Dr Haishan Jang, Chair and CEO of BRIM Biotechnology, commented: “Our two clinical trials have successfully demonstrated the strengths of our first-in-class lead asset BRM421, to treat and potentially cure dry eye syndrome. Millions of people world-wide are impacted by dry eye syndrome, with reported prevalence from 8% in the U.S. to rates higher than 30% in some regions of Taiwan and China. Currently, there is no permanent cure for dry eye syndrome, so we are particularly pleased with the results which confirm the disease-modifying effect of BRM421, and we are thrilled to be able to enter the next pivotal stage of clinical development.”

Image credit: Victor Freitas

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free